Cachexia and bladder cancer: clinical impact and management.

Area of Science:

• Oncology
• Metabolism
• Geriatrics

Background:

• Cachexia, a complex metabolic syndrome, is prevalent in bladder cancer patients.
• It is characterized by muscle loss and systemic inflammation, impacting treatment efficacy.
• Nutritional deficiencies exacerbate cachexia and sarcopenia in bladder cancer.

Purpose of the Study:

• To review the causes, management strategies, and clinical outcomes of cachexia in bladder cancer.
• To highlight the impact of cachexia and sarcopenia on patients undergoing radical cystectomy, chemotherapy, and radiation.
• To discuss current and emerging therapeutic interventions for cachexia in bladder cancer.

Main Methods:

• Literature review of studies on cachexia, sarcopenia, and bladder cancer.
• Analysis of clinical outcomes, including survival and treatment response.
• Synthesis of information on management approaches and investigational agents.

Main Results:

• Bladder cancer-related cachexia is linked to poorer survival and therapeutic outcomes.
• Cachectic patients experience increased postoperative complications after radical cystectomy.
• Investigational agents like magnolol, flucoidan, and Anamorelin show potential for cachexia management.

Conclusions:

• Effective cachexia management in bladder cancer necessitates early identification and a multidisciplinary approach.
• Nutritional support, physical therapy, and palliative care are crucial components.
• Further clinical trials are essential to establish optimal pharmacological treatments for bladder cancer cachexia.